This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Inspire Medical's (INSP) global presence.
Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients
by Zacks Equity Research
Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.
PDCO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Masimo's (MASI) Launch to Serve the Personalized Hearables Market
by Zacks Equity Research
Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.
QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod
by Zacks Equity Research
QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering
by Zacks Equity Research
Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.
Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe
by Zacks Equity Research
Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.
3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
by Zacks Equity Research
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.
Orthofix (OFIX) Advances in ALIF Procedure With New Launch
by Zacks Equity Research
Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.
Quest Diagnostics (DGX) Partners to Offer New Testing Service
by Zacks Equity Research
Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
by Zacks Equity Research
The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.